Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C. Motta I, et al. Among authors: berry c. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0053624. doi: 10.1128/aac.00536-24. Epub 2024 Jun 6. Antimicrob Agents Chemother. 2024. PMID: 38842323 Free PMC article. Clinical Trial.
Multidrug-resistant tuberculosis.
Nyang'wa BT, Berry C, Fielding K, Nunn AJ. Nyang'wa BT, et al. Among authors: berry c. Lancet. 2019 Jul 27;394(10195):298-299. doi: 10.1016/S0140-6736(19)30691-9. Lancet. 2019. PMID: 31354136 No abstract available.
Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.
du Cros P, Khamraev A, Tigay Z, Abdrasuliev T, Greig J, Cooke G, Herboczek K, Pylypenko T, Berry C, Ronnachit A, Lister D, Dietrich S, Ariti C, Safaev K, Nyang'wa BT, Parpieva N, Tillashaikhov M, Achar J. du Cros P, et al. Among authors: berry c. ERJ Open Res. 2021 Feb 8;7(1):00537-2020. doi: 10.1183/23120541.00537-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33585652 Free PMC article.
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
Nyang'wa BT, Kloprogge F, Moore DAJ, Bustinduy A, Motta I, Berry C, Davies GR. Nyang'wa BT, et al. Among authors: berry c. BMJ Open. 2021 Sep 6;11(9):e047185. doi: 10.1136/bmjopen-2020-047185. BMJ Open. 2021. PMID: 34489274 Free PMC article.
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. Berry C, et al. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8. Trials. 2022. PMID: 35698158 Free PMC article.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: berry c. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, Dodd M, Foraida S, Gegia M, Li M, Mirzayev F, Morgan H, Motta I, Nguyen L, Schumacher S, Schlub T, Fox G. Hasan T, et al. Among authors: berry c. Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653. Clin Infect Dis. 2024. PMID: 37874021 Free PMC article. Review.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Among authors: berry c. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, Liverko I, Usmanova R, Butabekov I, Moodliar R, Mbenga M, Rasool M, Nyang'wa BT, Berry C. Crocker-Buque T, et al. Among authors: berry c. Clin Infect Dis. 2024 Aug 16;79(2):569-570. doi: 10.1093/cid/ciad767. Clin Infect Dis. 2024. PMID: 38419566 Free PMC article. No abstract available.
2,367 results